Search results
Results from the WOW.Com Content Network
CimaVax-EGF is a vaccine used to treat cancer, specifically non-small-cell lung carcinoma (NSCLC). CIMAvax-EGF is composed of recombinant human epidermal growth factor (EGF) conjugated to a protein carrier. [2] The vaccine was developed by the Center of Molecular Immunology, Havana, Cuba, and made available to the Cuban population in 2011.
GVAX is a cancer vaccine composed of whole tumor cells genetically modified to secrete the immune stimulatory cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF), and then irradiated to prevent further cell division.
A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. [1] Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.
The GSK-Oxford Cancer Immuno-Prevention Programme has been launched on the back of several technological and scientific advances that have made the potential for vaccines against pre-cancer ...
These vaccines are made from antigens taken from the patient’s own cancer cells. Autologous vaccines have been used to treat lung cancer, [15] colorectal cancer, [16] melanoma, [17] renal cell cancer, [18] and prostate cancer. [19] Allogenic tumor cell vaccines; These vaccines are made from antigens taken from individuals other than the ...
The personalized anti-tumor vaccines are made of specific DNA to target mutated cancer genes. The DNA is derived from a patient’s own biopsy of their tumor. Roughly a third of the patients ...
The study involved 36 patients with hepatocellular carcinoma, the most common form of liver cancer. Patients were given custom-made vaccines on top of Merck's widely used immunotherapy Keytruda ...
NeuVax has been tested as adjuvant treatment in nearly 200 breast cancer patients over a total of 5 years, and has shown to be safe and effective in Phase 2 trials. [6] As a result, two additional NeuVax trials registered or underway are: (1) a 700 patient Phase 3 trial for FDA approval - not yet recruiting [2] [needs update] and (2) a 300 patient Phase 2 trial studying the combination of ...